---
document_datetime: 2025-12-02 05:08:37
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/prolia.html
document_name: prolia.html
version: success
processing_time: 0.1480418
conversion_datetime: 2025-12-24 16:47:53.468411
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Prolia

[RSS](/en/individual-human-medicine.xml/65507)

##### Authorised

This medicine is authorised for use in the European Union

denosumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Prolia](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-77354)
- [More information on Prolia](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Prolia is a medicine used to treat the following conditions:

- osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause Prolia reduces the risk of fractures in the spine and elsewhere in the body, including in the hip;
- bone loss in men receiving treatment for prostate cancer that increases their risk of Prolia reduces the risk of fractures in the spine;
- bone loss in adults at increased risk of fractures who are treated long term with corticosteroid medicines given by mouth or injection.

The medicine contains the active substance denosumab.

Expand section

Collapse section

## How is Prolia used?

Prolia is available as a solution for injection in prefilled syringes, each containing 60 mg denosumab.

Prolia is given once every 6 months as a 60 mg injection under the skin in the thigh, abdomen (belly) or back of the arm. During treatment with Prolia, the doctor should ensure that the patient is receiving calcium and vitamin D supplements. Prolia can be given by someone who has been trained in how to give injections appropriately.

The medicine can only be obtained with a prescription. For more information about using Prolia, see the package leaflet or contact your doctor or pharmacist.

## How does Prolia work?

The active substance in Prolia, denosumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a specific structure in the body called RANKL. RANKL is involved in activating osteoclasts, the cells in the body that are involved in breaking down bone tissue. By attaching to and blocking RANKL, denosumab reduces the formation and activity of the osteoclasts.

This reduces the loss of bone and maintains bone strength, making fractures less likely to happen.

## What benefits of Prolia have been shown in studies?

**Osteoporosis in women**

Prolia has been shown to be more effective than placebo (a dummy treatment) at reducing fractures in two main studies involving a total of over 8,000 women with osteoporosis who had been through the menopause. In the first of these studies, 2% of the women receiving Prolia had a new spine fracture after 3 years of treatment compared with 7% of the women receiving placebo. Prolia was also more effective at reducing the number of women who had fractures elsewhere in the body, including in the hip.

In the second study, the women were receiving treatment for breast cancer and were considered to be at high risk of fracture. Women who took Prolia had higher bone density (a measure of how strong the bones are) in the lumbar (lower) spine after 1 year of treatment than women on placebo.

**Osteoporosis in men**

Prolia has been compared with placebo in one main study involving 242 men with osteoporosis. In men who took Prolia bone density increased by 5.7% after 1 year of treatment compared with a 0.9% increase in men who took placebo.

**Bone loss in men receiving treatment for prostate cancer**

Prolia has been shown to be more effective than placebo at treating bone loss in one main study involving 1,468 men receiving treatment for prostate cancer who were at an increased risk of fracture. After 2 years, men who received Prolia had an increase in bone density in the lumbar spine that was 7% higher than in those who received placebo. In addition, after 3 years the risk of new spine fractures was lower in patients who received Prolia.

**Bone loss in adults receiving long-term corticosteroid therapy**

Prolia has been shown to be more effective than risedronate (a bisphosphonate medicine) at increasing bone density in one main study involving 795 adults treated with corticosteroid medicines. In patients who had been treated with corticosteroids for up to 3 months before the study, bone density in the lumbar spine increased by 3.1% after 1 year of treatment with Prolia compared with a 0.8% increase with risedronate. In patients who had been treated with corticosteroids for more than 3 months before the study, lumbar spine bone density increased by 3.6% after 1 year of treatment with Prolia

## What are the risks associated with Prolia?

The most common side effects with Prolia (seen in more than 1 patient in 10) are pain in the arms or legs, and bone, joint and muscle pain. Uncommon or rare cases of cellulitis (inflammation of deep skin tissue), hypocalcaemia (low blood calcium), hypersensitivity (allergy), osteonecrosis of the jaw (damage to the bones of the jaw, which could lead to pain, sores in the mouth or loosening of teeth) and unusual fractures of the thigh bone have been seen in patients taking Prolia.

Prolia must not be used in people with hypocalcaemia (low blood calcium levels). For the full list of side effects and restrictions with Prolia, see the package leaflet.

## Why is Prolia authorised in the EU?

The European Medicines Agency decided that Prolia's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Prolia?

The company that markets Prolia will provide a card to inform patients about the risk of osteonecrosis of the jaw and to instruct them to contact their doctor if they experience symptoms.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Prolia have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Prolia are continuously monitored. Side effects reported with Prolia are carefully evaluated and any necessary action taken to protect patients.

## Other information about Prolia

Prolia received a marketing authorisation valid throughout the EU on 26 May 2010.

Prolia : EPAR - Summary for the public

English (EN) (87.73 KB - PDF)

**First published:** 23/06/2010

**Last updated:** 12/09/2018

[View](/en/documents/overview/prolia-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-993)

български (BG) (116.97 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/bg/documents/overview/prolia-epar-summary-public_bg.pdf)

español (ES) (88.01 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/es/documents/overview/prolia-epar-summary-public_es.pdf)

čeština (CS) (113.91 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/cs/documents/overview/prolia-epar-summary-public_cs.pdf)

dansk (DA) (86.62 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/da/documents/overview/prolia-epar-summary-public_da.pdf)

Deutsch (DE) (88.85 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/de/documents/overview/prolia-epar-summary-public_de.pdf)

eesti keel (ET) (86.41 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/et/documents/overview/prolia-epar-summary-public_et.pdf)

ελληνικά (EL) (122.82 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/el/documents/overview/prolia-epar-summary-public_el.pdf)

français (FR) (88.93 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/fr/documents/overview/prolia-epar-summary-public_fr.pdf)

hrvatski (HR) (108.83 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/hr/documents/overview/prolia-epar-summary-public_hr.pdf)

italiano (IT) (86.98 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/it/documents/overview/prolia-epar-summary-public_it.pdf)

latviešu valoda (LV) (111.63 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/lv/documents/overview/prolia-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (112.54 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/lt/documents/overview/prolia-epar-summary-public_lt.pdf)

magyar (HU) (110.37 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/hu/documents/overview/prolia-epar-summary-public_hu.pdf)

Malti (MT) (114.99 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/mt/documents/overview/prolia-epar-summary-public_mt.pdf)

Nederlands (NL) (87.02 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/nl/documents/overview/prolia-epar-summary-public_nl.pdf)

polski (PL) (112.78 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/pl/documents/overview/prolia-epar-summary-public_pl.pdf)

português (PT) (87.76 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/pt/documents/overview/prolia-epar-summary-public_pt.pdf)

română (RO) (111.35 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/ro/documents/overview/prolia-epar-summary-public_ro.pdf)

slovenčina (SK) (111.95 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/sk/documents/overview/prolia-epar-summary-public_sk.pdf)

slovenščina (SL) (105.2 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/sl/documents/overview/prolia-epar-summary-public_sl.pdf)

Suomi (FI) (86.48 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/fi/documents/overview/prolia-epar-summary-public_fi.pdf)

svenska (SV) (86.84 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

12/09/2018

[View](/sv/documents/overview/prolia-epar-summary-public_sv.pdf)

Prolia : EPAR - Risk Management Plan

English (EN) (1.5 MB - PDF)

**First published:** 24/10/2023

**Last updated:** 10/01/2024

[View](/en/documents/rmp/prolia-epar-risk-management-plan_en.pdf)

## Product information

Prolia : EPAR - Product information

English (EN) (812.1 KB - PDF)

**First published:** 23/06/2010

**Last updated:** 22/10/2025

[View](/en/documents/product-information/prolia-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-390)

български (BG) (939.37 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/bg/documents/product-information/prolia-epar-product-information_bg.pdf)

español (ES) (889.51 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/es/documents/product-information/prolia-epar-product-information_es.pdf)

čeština (CS) (943.3 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/cs/documents/product-information/prolia-epar-product-information_cs.pdf)

dansk (DA) (899.63 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/da/documents/product-information/prolia-epar-product-information_da.pdf)

Deutsch (DE) (927.73 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/de/documents/product-information/prolia-epar-product-information_de.pdf)

eesti keel (ET) (876.85 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/et/documents/product-information/prolia-epar-product-information_et.pdf)

ελληνικά (EL) (940.96 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/el/documents/product-information/prolia-epar-product-information_el.pdf)

français (FR) (940.36 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/fr/documents/product-information/prolia-epar-product-information_fr.pdf)

hrvatski (HR) (908.5 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/hr/documents/product-information/prolia-epar-product-information_hr.pdf)

íslenska (IS) (880.2 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/is/documents/product-information/prolia-epar-product-information_is.pdf)

italiano (IT) (907 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/it/documents/product-information/prolia-epar-product-information_it.pdf)

latviešu valoda (LV) (905.17 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/lv/documents/product-information/prolia-epar-product-information_lv.pdf)

lietuvių kalba (LT) (932.5 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/lt/documents/product-information/prolia-epar-product-information_lt.pdf)

magyar (HU) (941.16 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/hu/documents/product-information/prolia-epar-product-information_hu.pdf)

Malti (MT) (1.03 MB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/mt/documents/product-information/prolia-epar-product-information_mt.pdf)

Nederlands (NL) (898.37 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/nl/documents/product-information/prolia-epar-product-information_nl.pdf)

norsk (NO) (887.53 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/no/documents/product-information/prolia-epar-product-information_no.pdf)

polski (PL) (921.89 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/pl/documents/product-information/prolia-epar-product-information_pl.pdf)

português (PT) (893.85 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/pt/documents/product-information/prolia-epar-product-information_pt.pdf)

română (RO) (917.71 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/ro/documents/product-information/prolia-epar-product-information_ro.pdf)

slovenčina (SK) (961.85 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/sk/documents/product-information/prolia-epar-product-information_sk.pdf)

slovenščina (SL) (908.46 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/sl/documents/product-information/prolia-epar-product-information_sl.pdf)

Suomi (FI) (890.4 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/fi/documents/product-information/prolia-epar-product-information_fi.pdf)

svenska (SV) (893.24 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

22/10/2025

[View](/sv/documents/product-information/prolia-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00000954/202409 17/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Prolia : EPAR - All Authorised presentations

English (EN) (14.68 KB - PDF)

**First published:** 23/06/2010

**Last updated:** 04/11/2016

[View](/en/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-771)

български (BG) (86.54 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/bg/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_bg.pdf)

español (ES) (12.23 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/es/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_es.pdf)

čeština (CS) (81.56 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/cs/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (14.83 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/da/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (12.19 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/de/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (14.86 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/et/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (81.55 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/el/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_el.pdf)

français (FR) (14.94 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/fr/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (23.66 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/hr/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (11.99 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/is/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_is.pdf)

italiano (IT) (12.11 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/it/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (89.84 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/lv/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (55.25 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/lt/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (83.02 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/hu/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (94.23 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/mt/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (22.58 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/nl/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_nl.pdf)

polski (PL) (91.43 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/pl/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_pl.pdf)

português (PT) (25.15 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/pt/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_pt.pdf)

română (RO) (87.79 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/ro/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (89.27 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/sk/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (87.87 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/sl/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (14.82 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/fi/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (25.25 KB - PDF)

**First published:**

23/06/2010

**Last updated:**

04/11/2016

[View](/sv/documents/all-authorised-presentations/prolia-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Prolia Active substance denosumab International non-proprietary name (INN) or common name denosumab Therapeutic area (MeSH)

- Bone Resorption
- Osteoporosis, Postmenopausal
- Osteoporosis

Anatomical therapeutic chemical (ATC) code M05BX04

### Pharmacotherapeutic group

Drugs for treatment of bone diseases

### Therapeutic indication

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia significantly reduces the risk of vertebral, non vertebral and hip fractures.

Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Prolia significantly reduces the risk of vertebral fractures.

## Authorisation details

EMA product number EMEA/H/C/001120 Marketing authorisation holder

Amgen Europe B.V.

Minervum 7061

Marketing authorisation issued 26/05/2010 Revision 34

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Prolia : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (142.77 KB - PDF)

**First published:** 18/06/2025

[View](/en/documents/procedural-steps-after/prolia-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Prolia : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (361.83 KB - PDF)

**First published:** 08/06/2011

**Last updated:** 22/10/2025

[View](/en/documents/procedural-steps-after/prolia-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Prolia-H-C-PSUSA-00000954-202409 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/305951/2025

English (EN) (128.65 KB - PDF)

**First published:** 22/10/2025

[View](/en/documents/scientific-conclusion/prolia-h-c-psusa-00000954-202409-epar-scientific-conclusions-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Prolia-H-C-PSUSA-00000954-201809 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/243844/2019

English (EN) (68.73 KB - PDF)

**First published:** 19/07/2019

[View](/en/documents/scientific-conclusion/prolia-h-c-psusa-00000954-201809-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Prolia-H-C-1120-II-0068 : EPAR - Assessment Report - Variation

Reference Number: EMA/CHMP/406583/2018

English (EN) (2.61 MB - PDF)

**First published:** 12/09/2018

**Last updated:** 12/09/2018

[View](/en/documents/variation-report/prolia-h-c-1120-ii-0068-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Prolia (II-68)

Adopted

Reference Number: EMA/CHMP/256922/2018

English (EN) (68.06 KB - PDF)

**First published:** 27/04/2018

**Last updated:** 27/04/2018

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prolia-ii-68_en.pdf)

Prolia-H-C-1120-II-0062 : EPAR - Assessment Report - Variation

Reference Number: EMA/493205/2017

English (EN) (1.14 MB - PDF)

**First published:** 25/08/2017

**Last updated:** 25/08/2017

[View](/en/documents/variation-report/prolia-h-c-1120-ii-0062-epar-assessment-report-variation_en.pdf)

Prolia-PSUSA-00000954-201609 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/502316/2017

English (EN) (60.68 KB - PDF)

**First published:** 02/08/2017

**Last updated:** 02/08/2017

[View](/en/documents/scientific-conclusion/prolia-psusa-00000954-201609-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Prolia-H-C-PSUSA-00000954-201409 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/638034/2015

English (EN) (67.02 KB - PDF)

**First published:** 28/09/2015

**Last updated:** 28/09/2015

[View](/en/documents/scientific-conclusion/prolia-h-c-psusa-00000954-201409-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Prolia-H-C-1120-II-0030 : EPAR - Assessment Report - Variation

Adopted

English (EN) (2.55 MB - PDF)

**First published:** 11/07/2014

**Last updated:** 11/07/2014

[View](/en/documents/variation-report/prolia-h-c-1120-ii-0030-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Prolia

Adopted

Reference Number: EMA/CHMP/208646/2014

English (EN) (74.44 KB - PDF)

**First published:** 25/04/2014

**Last updated:** 25/04/2014

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-prolia_en.pdf)

## Initial marketing authorisation documents

Prolia : EPAR - Public assessment report

English (EN) (732.33 KB - PDF)

**First published:** 23/06/2010

**Last updated:** 23/06/2010

[View](/en/documents/assessment-report/prolia-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Prolia

Adopted

Reference Number: EMA/CHMP/776168/2009

English (EN) (38.31 KB - PDF)

**First published:** 17/12/2009

**Last updated:** 17/12/2009

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-prolia_en.pdf)

#### News on Prolia

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2018) 27/04/2018

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2014) 25/04/2014

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Prolia : EPAR - Product information - tracked changes

English (EN) (3.13 MB - DOCX)

**First published:** 18/06/2025

**Last updated:** 22/10/2025

[View](/en/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-547)

български (BG) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/bg/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_bg.docx)

español (ES) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/es/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_es.docx)

čeština (CS) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/cs/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/da/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/de/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (3.11 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/et/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (3.14 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/el/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_el.docx)

français (FR) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/fr/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/hr/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (3.14 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/is/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_is.docx)

italiano (IT) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/it/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/lv/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (3.1 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/lt/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/hu/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (3.1 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/mt/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/nl/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/no/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_no.docx)

polski (PL) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/pl/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_pl.docx)

português (PT) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/pt/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_pt.docx)

română (RO) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/ro/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/sk/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/sl/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/fi/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (3.13 MB - DOCX)

**First published:**

18/06/2025

**Last updated:**

22/10/2025

[View](/sv/documents/product-information-tracked-changes/prolia-epar-product-information-tracked-changes_sv.docx)

#### More information on Prolia

- [EMEA-000145-PIP01-07-M09 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000145-pip01-07-m09)
- [EMEA-000145-PIP02-12-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000145-pip02-12-m05)
- [Periodic Knowledge, Attitudes, and Behavior (KAB) Survey of Certified Prescribers to Assess Understanding of the Risks with the Prolia Risk Evaluation and Mitigation of Strategy (REMS) (20240121) - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000393)
- [A Real-world, Prospective, Observational Study of Prolia® (20180401) - post-authorisation study](https://catalogues.ema.europa.eu/study/105188)
- [The Safety and Effectiveness of Denosumab Among Chinese With Osteoporosis and Glucocorticoid Exposure - a Real World Study in Taiwan (20220054) - post-authorisation study](https://catalogues.ema.europa.eu/study/49446)
- [Comparative Effectiveness of Osteoporosis Medications Among Female Medicare Fee-For-Service (FFS) Beneficiaries in the United States (20210028) - post-authorisation study](https://catalogues.ema.europa.eu/study/49180)
- [Prospective Observational Study to Describe Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France and its use in Routine Clinical Practice (20130240) - post-authorisation study](https://catalogues.ema.europa.eu/study/29204)
- [Occurrence of serious infection among patients with rheumatoid arthritis or psoriatic arthritis concurrently exposed to an immunosuppressive biologic and denosumab: US physician practice chart review study (20150207) - post-authorisation study](https://catalogues.ema.europa.eu/study/20935)
- [Prolia® Postmarketing Active Safety Surveillance Program for Soliciting Adverse Events of Special Interest in the United States (PASP-EMR Program) - post-authorisation study](https://catalogues.ema.europa.eu/study/48699)
- [Prospective Observational Study to Describe Characteristics and Management of Patients With Osteoporosis Treated With Prolia® in Routine Clinical Practice in Poland (20160178) - post-authorisation study](https://catalogues.ema.europa.eu/study/41269)
- [Postmarketing Surveillance Study of Prolia (Denosumab) in South Korea - post-authorisation study](https://catalogues.ema.europa.eu/study/39173)
- [Prolia® persistence in post-menopausal women with osteoporosis, over 70 years, at increased risk of fracture, treated in routine clinical practice in Bulgaria - post-authorisation study](https://catalogues.ema.europa.eu/study/37686)
- [The use, safety, and effectiveness of Prolia in clinical practice among Chinese women with post-menopausal osteoporosis ─ Taiwan and Hong Kong (20180325) - post-authorisation study](https://catalogues.ema.europa.eu/study/37411)
- [Burden of serious infection in patients with rheumatoid arthritis treated with Prolia ovserved in a clinical setting (20140127) - post-authorisation study](https://catalogues.ema.europa.eu/study/15158)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 22/10/2025

## Share this page

[Back to top](#main-content)